Nectin Therapeutics

Company Overview

Snapshot

Founded in January 2017 by Ofer Mandelboim and Pini Tsukerman, Nectin Therapeutics operates with 11–50 employees. The company has raised a total of $36 million across six funding rounds from seven investors.

Business overview

Nectin Therapeutics is a biotechnology company focused on developing next-generation immune-oncology (IO) therapies to improve outcomes for cancer patients. The company's core technology involves a diverse pipeline of targeted antibodies based on nectin pathways, designed to overcome tumor-deployed inhibitory mechanisms and enable immune cells to destroy cancer cells effectively. Additionally, Nectin Therapeutics develops CAR-T and -NK drivers that specifically target tumor cells in various indications, including hard-to-treat cancers, leveraging the unique expression patterns of several nectin proteins. The company operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development, serving the healthcare and pharmaceutical markets.

Strategic signal

Nectin Therapeutics reported encouraging Phase 1 results for its NTX1088 therapy in combination with Keytruda (pembrolizumab) at ASCO 2026. This positive clinical data indicates potential efficacy for their first-in-class immuno-oncology treatment, providing a strong validation signal for investors regarding the company's pipeline and its strategic collaboration with Merck.

Company Intelligence Q&A

What was the most recent funding event for Nectin Therapeutics?

In May 2024, Nectin Therapeutics completed an A Round of funding, with Guangzhou Sino-Israel Biotech Investment Fund (GIBF) participating.

What was a key development regarding Nectin Therapeutics' lead drug candidate in May 2023?

In May 2023, the Myeloma Investment Fund invested in.

When did Nectin Therapeutics initiate patient dosing for its NTX1088 clinical trial?

In November 2022, Nectin Therapeutics announced the initiation of patient dosing in a Phase 1 clinical trial for NTX1088, a first-in-class anti-PVR targeted immunotherapy for advanced solid tumors.

What collaboration did Nectin Therapeutics announce in February 2023?

In February 2023, Nectin Therapeutics announced a collaboration with Merck on a clinical trial of its anti-PVR antibody NTX1088 in combination with KEYTRUDA® (pembrolizumab) for patients with locally advanced and metastatic solid tumors.

What were the recent clinical trial results for NTX1088?

In June 2026, Nectin Therapeutics reported encouraging Phase 1 results for NTX1088 in combination with Keytruda (pembrolizumab) at ASCO 2026.